FDA approves Jeuveau to treat glabellar lines.- Evolus/Alphaeon

Evolus, Inc. has announced that the FDA has approved its lead product, Jeuveau, for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.

David Moatazedi, President and Chief Executive Officer of Evolus, stated, �Evolus is the first company in nearly a decade to enter the fast-growing U.S. aesthetic neurotoxin market. What makes Evolus unique is our focus on delivering performance beauty products with a customer-centric approach. We are pleased to introduce Jeuveau, the first FDA approved neurotoxin dedicated to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure� technology. Prior to our U.S. launch, we expect publication of our U.S. Phase III results and to submit for publication our European and Canadian head-to-head Phase III study versus Botox. Jeuveau is expected to be available throughout the United States at physician offices starting in Spring 2019".